The Companion Diagnostics Market Size, valued at USD 7.66 billion in 2023, is projected to grow at a robust CAGR of 11.9% to reach an estimated USD 21.15 billion by 2032, according to the latest market research. The substantial growth reflects the rising importance of personalized medicine, expanding oncology diagnostics, and ongoing advancements in biomarker-based testing platforms.

Companion diagnostics (CDx) are laboratory tests or imaging tools designed to determine a patient’s eligibility for a specific drug or therapy based on molecular and genetic biomarkers. These tools have become increasingly essential in guiding treatment decisions in oncology, cardiology, infectious diseases, and other therapeutic areas.

Get Free Sample Report on Companion Diagnostics Market size  

https://www.snsinsider.com/sample-request/2915

Key Drivers of Market Growth

  1. Rising Adoption of Precision Medicine
    Personalized medicine has transformed the healthcare landscape, focusing on targeted treatment based on individual genetic profiles. Companion diagnostics play a crucial role in tailoring therapies to improve efficacy and reduce adverse effects. Governments and private institutions globally are investing heavily in precision healthcare, creating a favorable environment for the expansion of CDx technologies.
  2. Increasing Cancer Prevalence and Targeted Therapies
    Cancer diagnostics remains the largest and fastest-growing application segment in the companion diagnostics market. With the rapid rise in cancer incidence worldwide, the need for targeted therapies that can address specific mutations or biomarkers has grown substantially. CDx tests are often co-developed with cancer drugs to identify responsive patient populations.
  3. Regulatory Approvals and Industry Collaborations
    Agencies such as the U.S. FDA, EMA, and PMDA have accelerated approvals of companion diagnostics alongside new therapeutic agents. Strategic partnerships between pharmaceutical companies and diagnostics developers—like those between Roche and Foundation Medicine or Thermo Fisher and Illumina—are driving innovation and commercial success.
  4. Technological Advancements in Genomics and Molecular Diagnostics
    Breakthroughs in next-generation sequencing (NGS), liquid biopsies, and real-time PCR platforms have expanded the diagnostic capabilities of CDx tools. These technologies allow multi-gene panels and non-invasive testing methods, improving clinical outcomes and patient compliance.
  5. Increased Clinical Trial Integration
    Pharmaceutical companies are increasingly incorporating companion diagnostics into clinical trial designs to stratify patient populations, enhance clinical endpoints, and secure faster regulatory approvals. This integration helps reduce drug development costs and failure rates, making CDx an indispensable tool in R&D strategies.

Key Segmentation

By Technology

  • Polymerase Chain Reaction
  • Immunohistochemistry
  • In-situ Hybridization
  • Next Generation Gene Sequencing
  • Others

By Indication

  • Cancer
  • Neurological Diseases
  • Infectious Diseases
  • Others

By End-user

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations (CROs)

 

Key Companies Profiled

Recent Developments

  • September 2024: Roche received FDA approval for a new CDx assay to identify patients eligible for its novel lung cancer drug.
  • January 2024: Thermo Fisher Scientific expanded its collaboration with Moderna to develop companion diagnostics for mRNA-based therapies targeting rare genetic disorders.
  • October 2023: Qiagen launched a CE-IVD approved liquid biopsy CDx kit for non-small cell lung cancer (NSCLC), enabling non-invasive detection of EGFR mutations.
  • August 2023: Illumina and Bristol Myers Squibb partnered to explore CDx applications in immunotherapy across multiple cancer indications.

Opportunities and Challenges

Opportunities:

  • Rapid integration of artificial intelligence in CDx data interpretation
  • Expansion into rare diseases and non-oncology indications
  • Emerging markets in Asia and Latin America with untapped potential
  • Regulatory harmonization and international collaboration to accelerate approvals

Challenges:

  • High development and validation costs
  • Complex regulatory pathways and varying global standards
  • Limited reimbursement for newer diagnostic technologies
  • Need for skilled professionals and advanced lab infrastructure

Future Outlook

The companion diagnostics market is poised for sustained growth over the next decade. As precision medicine becomes the standard of care, the synergy between therapeutic development and diagnostics will be crucial. CDx is not just a tool for identifying appropriate therapies—it is becoming a key pillar in value-based and patient-centered care models.

By 2032, with a projected valuation of USD 21.15 billion, the market will reflect advancements in genomic medicine, increased collaboration between stakeholders, and growing global access to targeted therapies.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)